9 / 1082
Proffered Papers
Dosimetry and detector development . ...........................................................................Abs. 530-535
Novel methods for auditing ..........................................................................................Abs. 536-541
Patient safety and treatment outcome ...........................................................................Abs. 542-547
Poster Viewing
Session 12: Gynaecology and prostate . .........................................................................Abs. 548-554
TUESDAY 9 MAY 2017
Teaching lecture
New radiotherapeutic horizons in soft tissue sarcoma treatment .............................................. Abs. 555
Clinical evidence for hypofractionation in prostate cancer what is the optimum? ......................... Abs. 556
Extracellular vesicles in radiation oncology ........................................................................... Abs. 557
Update on molecular radiotherapy ....................................................................................... Abs. 558
Basics, implementations, limitations, … of Monte Carlo dose calculation algorithms .................... Abs. 559
RTTs roles and responsibilities to support future practice ........................................................ Abs. 560
Symposium
Radiotherapy in the elderly ..........................................................................................Abs. 561-564
Symposium with Proffered Papers
Selection of patients and radiotherapy technique for APBI in the light
of new phase III trial data . ..........................................................................................Abs. 565-569
Novel approaches in poor tumour control sites ................................................................Abs. 570-573
Symposium
4D imaging and tracked delivery ...................................................................................Abs. 574-576
Modelling and treatment customisation ..........................................................................Abs. 577-579
RT is technology driven. How to keep the patient involved? . .............................................Abs. 580-582
Hypofractionation in prostate cancer . ............................................................................Abs. 583-585
Is there any ground for boost brachytherapy in the time of high precision IGRT/IMRT? .........Abs. 586-588
Symposium with Proffered Papers
Novel approaches in tumour control ..............................................................................Abs. 589-591
Symposium
Applications and challenges in dosimetry for MR-linacs .....................................................Abs. 592-594
Novel approaches for combining imaging and non-imaging data
for radiotherapy response predicition .............................................................................Abs. 595-597
Debate
Debate: Precision in radiotherapy: mission complete! . ........................................................... Abs. 598
POSTERS
Clinical track: Head and Neck .......................................................................................Abs. 603-621
Clinical track: CNS ......................................................................................................Abs. 622-644
Clinical track: Haematology ..........................................................................................Abs. 645-648
Clinical track: Breast ...................................................................................................Abs. 649-665
Clinical track: Lung .....................................................................................................Abs. 666-678
Clinical track: Upper GI (oesophagus, stomach, pancreas, liver) ........................................Abs. 679-701
Clinical track: Lower GI (colon, rectum, anus) . ...............................................................Abs. 702-707
Clinical track: Gynaecological (endometrium, cervix, vagina, vulva) ...................................Abs. 708-722
Clinical track: Prostate ................................................................................................Abs. 723-739
Clinical track: Skin cancer / malignant melanoma ............................................................Abs. 740-741
Clinical track: Sarcoma ................................................................................................Abs. 742-744
Clinical track: Palliation ...............................................................................................Abs. 745-747
Clinical track: Elderly ..................................................................................................Abs. 748-749
Clinical track: Health services research / health economics ...............................................Abs. 750-751
Clinical track: Other ....................................................................................................Abs. 752-755
Physics track: Basic dosimetry and phantom and detector development ..............................Abs. 756-784
Physics track: Dose measurement and dose calculation ....................................................Abs. 785-812
Physics track: Radiation protection, secondary tumour induction
and low dose (incl. imaging) . .......................................................................................Abs. 813-815
Physics track: Treatment plan optimisation: algorithms ....................................................Abs. 816-823
Physics track: Treatment planning: applications ..............................................................Abs. 824-845
Physics track: (Radio)biological modelling ......................................................................Abs. 846-855
Physics track: Intra-fraction motion management ............................................................Abs. 856-865
Physics track: Inter-fraction motion management (excl. adaptive radiotherapy) ...................Abs. 866-874
Physics track: Adaptive radiotherapy for inter-fraction motion management ........................Abs. 875-880